Treatment

Before we learned that Artesunate might inhibit XMRV via NF Kappa B inhibition in August of 2009, we were aware that Artesunate was a known inhibitor of all known human herpes viruses against which it has been tested as well as HIV. I was first introduced to Artesunate by a prominent Autism expert at a medical conference who finds it helpful in Autism. We were also impressed that Artesunate and its relative Wormwood, using SL administration on the echo table, produced the most powerful ablation of oxygen toxicity as well as the ablation of other echo terrain map (ETM) backflashes than any other therapy we have ever used. Both Artesunate and Wormwood will do this in 30 seconds.

I have tested a patient’s response to various vitamin E preparations on the ETM plus a typical array of nutrients that are standard practice in my clinic – Methyl-B12, Hydroxy-B12, Glucose, Fructose, Olive Oil and Fish Oil. The last six always show this kind of response in CFS but not in controls who are all positive for these six except Fructose which can be mixed in controls. CoQ-10 response can be mixed positive or negative in CFS but positive in controls. The historical variance for IVRT testing is plus or minus 1% and IVRT is measured three times and averaged. IVRT is an indirect measure of the free energy in the heart myocardial cells. Positive is good and negative is bad as it indicates a loss of free energy. These immediate responses in IVRT over a few minutes may or may not reflect later effects over time but are rather more useful to detect immediate positive or negative effects. Later effects can also be monitored but requires sequential testing over months of many patients on the same nutrient. This had only been done for a few items we currently use in therapy.

I have advised all my patients and their families to take 2000 IU of Vitamin D during this H1N1 crisis who can tolerate it and to go on Insosine at 500 mg BID and ramp it up to 1500 mg BID if exposed to or infected with H1N1. We have had only one case of H1N1 in a non-CFS adult child of a CFS case who reportedly did well on ramped Inosine but we don’t know what would have happened if she had not done that. Inosine can reduce death rates by viral infections, even when given late.

When I added Artsesunate to my complete protocol including CSF’s with pre-treatments, GMP and dietary changes a year ago, it seemed that overall, the clinical responses significantly improved and I saw a large number of patients completely resolve their diastolic dysfunction over time which I had never seen before I added Artesunate. The dogma in Cardiology is that diastolic dysfunction, once apparent, never goes away completely on echo. That is not true here and it began to be seen when we added Artesunate to an admittedly already complex protocol. All my stem cell patients are on this protocol as well. The stem cell patients show the most improvement on echo including ETM and diastolic dysfunction via standard echo. They are, however, on a complex protocol in addition to stem cells.

What is interesting about CFS is that as a group they are very immune activated and this immune activation includes the ant-viral pathway RNAse-L. As a group, they typically are resistant to acquiring the flu and I cannot remember a single case of severe morbidity or mortality from influenza in a CFS case in 25 years of practice in CFS. On the other hand, there are numerous examples of vaccine induced relapses of CFS, sometimes lasting for months and occasionally severe. I conclude that the risk benefit analysis shifts more towards not vaccinating than vaccinating. This may shift back however, as the CFS case gets less severe and the patient is working and exposed to crowds or is under 40 or pregnant in the case of N1H1.

When deciding when to use the CSF mixtures, hereafter called the Catabolic CSF Mixture (Heart, Brain and Pancreas) and the Anabolic CSF Mixture (Pancreas, Liver and Kidney), it is important to understand or “grok” your own catabolic period and your own anabolic period of the day.

This treatment update discusses the uses and various strategies to improve the effectiveness of cell signaling factors based on actual clinical examples and patient experiences. Both positive and negative results are discussed and practical solutions to improve outcomes are detailed.

This discussion explores the potential complications of Artesunate with two examples cited in patients.

In this discussion, Dr. Cheney explores the opposite approaches of anti-oxidative vs. pro-oxidative therapies. It is important to recognize that both may be useful but in the highly oxidizing environment of CFS, one may be more appropriate than the other and much safer.

This discussion encompasses the Gibbs Free Energy equation as it relates to the echocardiographic measurement of IVRT and the implications of both to the pathophysiology of CFS.